IDNT
Irbesartan Diabetic Nephropathy Trial
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.
N
1.715
Design
Double-blind RCT, three arms
Endpunkt
Doubling of creatinine, ESRD or death
Relevanz
1
ErgebnisIrbesartan vs placebo HR 0.80 (p=0.02); vs amlodipine HR 0.77 (p=0.006).
Lewis EJ, et al. N Engl J Med. 2001;345(12):851-860. 10.1056/NEJMoa011303
Diskussion & Kritik
Showed renoprotection is independent of the calcium-channel-blocker comparator and of the blood-pressure effect.